Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
News|Articles|September 24, 2019
ASEPCO Opens New California Facility
Author(s)Pharmaceutical Technology Editors
The new site will provide employees with more space, enhanced R&D facilities, and a fully functional sanitary products training center.
Advertisement
ASEPCO, a Watson-Marlow Fluid Technology Group bioprocessing applications manufacturing company, announced the opening of its new facility in Milpitas, CA, for expanded research and warehouse space.
The new site will provide employees with more space, enhanced R&D facilities, and a fully functional sanitary products training center, according to a Sept. 23, 2019 press release.
“We are delighted to be moving into our new expanded facility,” said Bill Mandel, president of ASEPCO, in the press release. “ASEPCO is committed to providing the highest quality bioprocessing valves. This move will enable us to enhance the services we offer and with our new state-of-the-art R&D facilities, to continue to develop the best products for all our customers’ biotechnology and pharmaceutical applications.”
Source:
Advertisement
Related to this article
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
Ronald Piervincenzi, USP, explains why manufacturers should act now and how benchmarking could reward reliable generic drug suppliers.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
The agency issued a direct final rule that supports the use of innovative testing methods to limit the use of animals and maintain existing safety standards.
The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Tavapadon Sets Development Benchmark for Parkinson's
2
KRAS G12D Inhibitor's $2.13B Deal Tests Cross-Border Tech Transfer
3
Weekly Basal Insulin Efsitora: A New Biologics CMC Benchmark
4
PharmTech’s Weekly Roundup—September 25, 2026
5